The latest update is out from ELEVAI Labs Inc. ( (ELAB) ).
On April 24, 2025, Northstrive Biosciences Inc. announced receiving positive preliminary responses from the FDA regarding their nonclinical studies and clinical development plans for EL-22, in combination with GLP-1 receptor agonists, aimed at treating obesity. The FDA’s feedback supports Northstrive’s plan to file an IND application for a Phase 2 clinical trial, marking a significant milestone in addressing the challenge of muscle preservation in obesity treatments, with ongoing preparations for production of EL-22.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Underperform.
ELEVAI Labs Inc.’s stock score is significantly impacted by its poor financial performance, characterized by negative revenue and cash flow. The adverse technical indicators further emphasize the stock’s downward trajectory. Additionally, valuation concerns with a negative P/E ratio contribute to a lower score. Despite positive industry news, these do not directly influence ELEVAI Labs Inc., leaving the corporate events factor out of consideration.
To see Spark’s full report on ELAB stock, click here.
More about ELEVAI Labs Inc.
Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., is a biopharmaceutical company focusing on the development and acquisition of innovative aesthetic medicines. Their lead asset, EL-22, uses an engineered probiotic approach to address the issue of muscle preservation during weight loss treatments, particularly with GLP-1 receptor agonists.
YTD Price Performance: -81.85%
Average Trading Volume: 431,496
Technical Sentiment Signal: Buy
Current Market Cap: $1.97M
For an in-depth examination of ELAB stock, go to TipRanks’ Stock Analysis page.